Outlook Therapeutics, INC 8-K filings

Outlook Therapeutics, Inc. has entered into an underwriting agreement for a public offering of common stock and accompanying warrants, anticipating gross proceeds of approximately $13.0 million.

Outlook Therapeutics remains on track for the planned commercial launch of LYTENAVA in Europe and anticipates a potential FDA approval decision in the U.S. for ONS-5010 in Q3 2025.

Outlook Therapeutics grants a $237,500 retention bonus opportunity to CFO and Interim CEO Lawrence A. Kenyon, payable upon continued service through December 31, 2025.

Outlook Therapeutics has announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for ONS-5010, setting a PDUFA goal date of August 27, 2025.

Outlook Therapeutics obtained a $33.1 million convertible note to repay existing debt and increased its authorized common stock shares to 260 million.

Outlook Therapeutics has resubmitted its Biologics License Application (BLA) for ONS-5010 to the U.S. Food and Drug Administration (FDA).

Outlook Therapeutics reports its first fiscal quarter 2025 results, highlighting progress towards commercializing LYTENAVA in Europe and resubmitting its BLA in the US for wet AMD treatment.

Outlook Therapeutics enters into a securities purchase agreement for $33.1 million to refinance existing debt and support its ONS-5010 development program.

Outlook Therapeutics is set to raise approximately $20.5 million through warrant exercises and plans to resubmit its Biologics License Application (BLA) for ONS-5010 in the first quarter of 2025.

Outlook Therapeutics announced its fiscal year 2024 financial results, highlighted by the European and UK approval of LYTENAVA for wet AMD and plans for a commercial launch in 2025.

Outlook Therapeutics has reduced its workforce by approximately 23% to lower operating expenses and preserve capital, incurring an estimated $0.3 million in restructuring charges.

Outlook Therapeutics' CEO, C. Russell Trenary III, has stepped down, and CFO Lawrence A. Kenyon has been appointed as Interim CEO, effective immediately.

Outlook Therapeutics' NORSE EIGHT trial for ONS-5010 in wet AMD did not meet its primary endpoint, but showed improvement in vision and a favorable safety profile, with a BLA resubmission planned for early 2025.

Outlook Therapeutics reports positive financial results for Q3 2024, highlighted by EU and UK marketing authorization for LYTENAVA and progress in the NORSE EIGHT clinical trial.

Outlook Therapeutics has secured marketing authorization from the UK's MHRA for LYTENAVA, a bevacizumab formulation for treating wet age-related macular degeneration.

Outlook Therapeutics has received European Commission approval for LYTENAVA, the first and only authorized ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration in the EU.

Outlook Therapeutics reports positive regulatory progress in Europe and the UK, advances its NORSE EIGHT clinical trial in the US, and provides a financial update for the second quarter of fiscal year 2024.

Outlook Therapeutics has submitted a Marketing Authorization Application to the UK's MHRA for its ONS-5010/LYTENAVA treatment for wet age-related macular degeneration, following a positive opinion from the EU's CHMP.

Outlook Therapeutics, Inc. has officially moved its corporate headquarters to a new location in Iselin, New Jersey, effective May 1, 2024.

Outlook Therapeutics completed a private placement with Syntone Ventures, issuing shares and warrants for a total of $7.00 per share and accompanying warrant.

Outlook Therapeutics has amended its at-the-market sales agreement with BTIG, increasing the potential offering of common stock to approximately $93.7 million.

Outlook Therapeutics has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement.

Outlook Therapeutics has awarded stock options to its CEO, CFO, CCO, and a Senior Advisor, with vesting tied to both time and performance milestones.

Outlook Therapeutics finalized a private placement of shares and warrants, and executed a 1-for-20 reverse stock split, significantly altering its share structure.

Outlook Therapeutics' stockholders approved an increase in authorized shares and other key proposals at the 2024 Annual Meeting, while rejecting a proposal related to officer exculpation.

Outlook Therapeutics announced its first quarter fiscal year 2024 financial results and provided a corporate update, highlighting progress on its ONS-5010 regulatory pathway and a significant financing agreement.

Outlook Therapeutics has secured up to $172 million in funding and received FDA agreement on a key clinical trial protocol for its ONS-5010 drug.